Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

10,285

Participants

Timeline

Start Date

January 22, 2022

Primary Completion Date

April 1, 2022

Study Completion Date

October 27, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Aerosolized Ad5-nCoV

Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.

BIOLOGICAL

Inactivated SARS-CoV-2 vaccine

Inactivated SARS-CoV-2 vaccine is homologous to the priming series which have been administered to the subjects, produced by SinoVac Biotech Co,. Ltd, Beijing Institute of Biological Products Co,. Ltd, Wuhan Institute of Biological Products Co,. Ltd, or Biokangtai.

Trial Locations (1)

210009

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

All Listed Sponsors
collaborator

Anhui Provincial Center for Disease Control and Prevention

UNKNOWN

collaborator

Shandong Province Centers for Disease Control and Prevention

OTHER

collaborator

Hunan Provincial Center for Disease Control and Prevention

OTHER

collaborator

Yunnan Center for Disease Control and Prevention

OTHER

collaborator

Chongqing Center for Disease Control and Prevention

OTHER

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK